Cancer Therapeutics and Biotherapeutics Market (By Application: Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Others; By Top Selling Drugs: Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade; By Product Type: Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy, Others; By End User: Consumption, Household, Hospital) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Therapeutics and Biotherapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Therapeutics and Biotherapeutics Market, by Product Type, 2023-2032
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Radiation Therapy
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Hormone Therapy
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Biotherapy
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
9.1. Cancer Therapeutics and Biotherapeutics Market, by End User, 2023-2032
9.1.1. Consumption (Sales)
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Household
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Hospital
9.1.3.1. Market Revenue and Forecast (2020-2032)
10.1. Cancer Therapeutics and Biotherapeutics Market, by Application Type, 2023-2032
10.1.1. Blood Cancer
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Lung Cancer
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Colorectal Cancer
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Prostate Cancer
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Breast Cancer
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Cervical Cancer
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Head and Neck Cancer
10.1.7.1. Market Revenue and Forecast (2020-2032)
10.1.8. Giloblastoma
10.1.8.1. Market Revenue and Forecast (2020-2032)
10.1.9. Malignant Meningioma
10.1.9.1. Market Revenue and Forecast (2020-2032)
10.1.10. Others
10.1.10.1. Market Revenue and Forecast (2020-2032)
11.1. Cancer Therapeutics and Biotherapeutics Market, by Top Selling Drugs Type, 2023-2032
11.1.1. Revlimid
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Herceptin
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Rituxan
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Opdivo
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2020-2032)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by End User (2020-2032)
12.1.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by End User (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by End User (2020-2032)
12.2.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by End User (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by End User (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by End User (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by End User (2020-2032)
12.3.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by End User (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by End User (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by End User (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by End User (2020-2032)
12.4.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by End User (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by End User (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by End User (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by End User (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by End User (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Top Selling Drugs Type (2020-2032)
13.1. Amgen Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Celgene Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ELI Lilly and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Hoffmann-La Roche AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. EnGeneIC Ltd
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Co Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample